The estimated Net Worth of Marc H Hedrick is at least $1.21 Milione dollars as of 10 September 2024. Marc Hedrick owns over 8,000 units of Plus Therapeutics stock worth over $27,574 and over the last 19 years he sold PSTV stock worth over $4,053. In addition, he makes $1,173,910 as Chief Executive Officer e Director at Plus Therapeutics.
Sign up
Marc Hedrick PSTV stock SEC Form 4 insiders trading
Marc has made over 26 trades of the Plus Therapeutics stock since 2006, according to the Form 4 filled with the SEC. Most recently he bought 8,000 units of PSTV stock worth $9,840 on 10 September 2024.
The largest trade he's ever made was buying 20,000 units of Plus Therapeutics stock on 7 May 2009 worth over $45,600. On average, Marc trades about 3,509 units every 138 days since 2006. As of 10 September 2024 he still owns at least 20,425 units of Plus Therapeutics stock.
You can see the complete history of Marc Hedrick stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Marc Hedrick biography
Dr. Marc H. Hedrick M.D. serves as Chief Executive Officer, Director of the Company. He is appointed as President of the Company in May 2004, and joined us as Chief Scientific Officer, Medical Director and Director in October 2002. In December 2000, Dr. Hedrick co-founded and served as President and Chief Executive Officer and Director of StemSource, Inc., a company specializing in stem cell research and development, which was acquired by the Company in 2002. He is a plastic surgeon and is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, he directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick earned his M.D. degree from University of Texas Southwestern Medical School, Dallas and an M.B.A. from UCLA Anderson School of Management. Dr. Hedrick’s qualifications to sit on our Board of Directors include his experience as a general, vascular and plastic surgeon; his academic appointments and achievements in the life sciences; his executive and managerial experience in stem cell research and scientific product development, and his foundational knowledge, experience and contributions to the specific technology and operations of our company. In addition, Dr. Hedrick has extensive global experience and familiarity with the cell therapy and regenerative medical industry. On April 2, 2014 the Board of Director’s appointed Dr. Hedrick as Chief Executive Officer.
What is the salary of Marc Hedrick?
As the Chief Executive Officer e Director of Plus Therapeutics, the total compensation of Marc Hedrick at Plus Therapeutics is $1,173,910. There are no executives at Plus Therapeutics getting paid more.
What's Marc Hedrick's mailing address?
Marc's mailing address filed with the SEC is C/O PLUS THERAPEUTICS INC., 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN, TX, 78756.
Insiders trading at Plus Therapeutics
Over the last 5 years, insiders at Plus Therapeutics have traded over $4,518 worth of Plus Therapeutics stock and bought 251,584 units worth $410,360 . The most active insiders traders include Greg Petersen, Marc H Hedrick e Richard J Hawkins. On average, Plus Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $8,201. The most recent stock trade was executed by Marc H Hedrick on 10 September 2024, trading 8,000 units of PSTV stock currently worth $9,840.
What does Plus Therapeutics do?
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
What does Plus Therapeutics's logo look like?
Complete history of Marc Hedrick stock trades at Plus Therapeutics
Plus Therapeutics executives and stock owners
Plus Therapeutics executives and other stock owners filed with the SEC include:
-
Marc Hedrick,
Chief Executive Officer, Director -
Dr. Marc H. Hedrick M.D.,
Pres, CEO & Director -
Steven Kesten,
President and Chief Medical Officer -
Seijiro Shirahama,
President , Asia Pacific -
Annigje van Es-Johansson,
Independent Director -
Greg Petersen,
Independent Director -
Robert Lenk,
Independent Director -
Howard Clowes,
Independent Director -
Mark Marino,
Chief Medical Officer -
Jeremy Hayden,
Vice President - Business Development, General Counsel -
Desiree Smith,
Principal Accounting Officer, Corporate Controller -
Gregory Stein,
Senior Vice President of Clinical Development -
Andrew Sims,
Chief Financial Officer, Vice President - Finance -
Richard Hawkins,
Chairman of the Board -
Dr. Norman D. LaFrance FACNP, FACP, M.D.,
Chief Medical Officer & Sr. VP -
Desiree Smith,
Corp. Controller, Principal Financial & Accounting Officer -
Gary S. Titus CPA,
Advisor -
Russ Havranek M.B.A., M.S.,
VP of Corp. Strategy, New Product Planning & Investor Relations -
Dr. John K. Fraser,
Chief Scientist -
Andrew J. Sims,
VP of Fin. & CFO -
Es Johansson An Van,
-
Norman D. La France,
Chief Medical Officer